Key result
Alogliptin significantly reduced intimal hyperplasia compared with saline (1087±127 vs 1896±140 μm²; P<0.001) in LKO mice 2 weeks after femoral artery injury.
Why the study?
Does alogliptin reduce intimal hyperplasia and arterial inflammation in atherogenic low-density lipoprotein receptor-deficient mice after femoral artery injury?
Does alogliptin reduce intimal hyperplasia and arterial inflammation in atherogenic low-density lipoprotein receptor-deficient mice after femoral artery injury?
Absolute Event Rate: 1087% vs 1896%
p-value: p=<0.001
Alogliptin suppresses neointimal formation and arterial inflammation after vascular injury in atherogenic mice, independent of its effects on glucose or cholesterol metabolism.
Does not support clinical use; extends preclinical data on DPP-4 inhibition in atherogenic vascular injury models.
BACKGROUND: The results of recent studies suggest that dipeptidyl-peptidase-4 inhibitors have antiatherogenic effects. However, whether or not dipeptidyl-peptidase-4 inhibitors could suppress arterial inflammation and intimal hyperplasia after injury remains undetermined. The present study aims to clarify the anti-inflammatory effects of the dipeptidyl-peptidase-4 inhibitor, alogliptin (AGP), on the arteries of atherogenic low-density lipoprotein receptor-deficient (LKO) mice. METHODS AND RESULTS: We compared intimal hyperplasia in LKO mice 2 weeks after femoral artery injury using an external vascular cuff model. All mice received oral injection of AGP (20 mg/kg per day) or normal saline (control) once daily for 14 days. Fasting blood sugar levels, serum cholesterol levels, or blood pressure did not significantly differ between the 2 groups. Plasma levels of active glucagon-like peptide-1 were higher in the AGP than in the control LKO mice (22.2±1.9 versus 15.6±0.9 pg/mL; P<0.05). Compared with saline, AGP significantly reduced intimal hyperplasia (1087±127 versus 1896±140 μm(2); P<0.001) as well as the intima/media ratio (0.08±0.01 versus 0.16±0.02; P<0.001). Immunostaining showed that AGP reduced proliferating cells (proliferating cell nuclear antigen-positive nuclei; P<0.001), percent smooth-muscle cell area (α-SMA-positive cells; P<0.001), inflammatory cells infiltration (lymphocyte antigen 6 complex-positive cells; P<0.05), tumor necrosis factor-α expression (P<0.05), and percent phospho-NF-κB-positive cell compared with saline. Levels of tumor necrosis factor -α (0.5-fold P<0.05), monocyte chemoattractant protein 1 (0.3-fold P<0.01), and interleukin-1β (0.2-fold P<0.05) mRNA were lower in the injured arteries of the AGP than in the control group. CONCLUSIONS: AGP appeared to suppress neointimal formation by inhibiting inflammation, independently of its effects on glucose or cholesterol metabolism in atherogenic LKO mice.
No takes yet. Share an insight, caveat, or question.
Akita et al. (2015) studied Arterial inflammation and intimal hyperplasia. Alogliptin vs. Normal saline was evaluated on Intimal hyperplasia (μm²) (p=<0.001). Alogliptin significantly reduced intimal hyperplasia compared with saline (1087±127 vs 1896±140 μm²; P<0.001) in LKO mice 2 weeks after femoral artery injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: